BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Federal Trade Commission Derides Warner Chilcott, PLC (WCRX) And "Product Hopping"


11/28/2012 7:45:22 AM

In its latest bid to level the playing field for generic drugs, the US Federal Trade Commission has filed a supportive brief in a lawsuit charging Warner Chilcott with concocting various schemes to thwart generic competition for its Doyrx acne pill. The lawsuit was filed last July by Mylan Laboratories, which claims the tactics were anticompetitive and cost consumers and taxpayers hundreds of millions of dollars. At issue is a concept called product switching or product hopping in which a brand-name drugmaker makes modest reformulations that purportedly offer little or no therapeutic advantages, but cause generic drugmakers to reformulate their own aspiring copycat versions. Such tactics can delay generic entries into the marketplace and, as a result, forestall competition that, presumably, would offer lower prices to consumers and government programs. And this is what Mylan accuses Warner Chilcott of doing several times over the past few years. To keep generic competition at bay, Warner Chilcott (WCRX) allegedly converted the market from Doryx capsules to tablets; released a study for administering Doryx with applesauce and sought a labeling change to require generic rivals to develop tablets that could be sprinkled over applesauce; and added scores, or lines, on Doryx tablets so patients would presumably find it easier to divide a tablet into thirds, court documents state.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->